The c-MET proto-oncogene encodes the Hepatocyte Growth Factor (HGF) receptor (Naldini et al., 1991b,c; Bottaro et al., 1991) , a trans-membrane protein with tyrosine kinase activity (Giordano et al., 1989; Park et al., 1987) . HGF is secreted by mesenchymal/stromal cells, and acts in a paracrine way on neighboring Met-expressing epithelial cells. HGF elicits a variety of biological responses, exerting control on cell dissociation, motility, invasion, proliferation and survival of dierent cell types. In vivo, HGF is involved in liver, kidney and lung regeneration and plays a crucial role in embryo development (for a review see Tamagnone and Comoglio, 1997) .
Originally, the c-MET proto-oncogene was identi®ed as an oncogene activated in vitro after treatment of a human cell line with a chemical carcinogen (Cooper et al., 1984) . In this cell line, activation of the Met protooncogene occurred via a chromosomal rearrangement between chromosome 1 and chromosome 7 (Park et al., 1986) . This rearrangement creates a hybrid gene, TPR-MET, with its upstream region derived from the TPR locus (Translocated Promoter Region) fused to downstream sequences encoding the Met kinase. In the fusion, the 5' region of the MET gene is replaced by TPR, which provides two leucine zipper domains. These motifs mimic the eect of the ligand leading to a constitutively dimerized and therefore activated Met kinase. The dimerization domains are essential for TPR-MET oncogene transforming activity (Rodrigues and Park, 1993) .
Tpr-Met-mediated cell transformation strongly depends on its kinase activity. The major autophosphorylation sites, located within the tyrosine kinase domain, are Tyr 365 and Tyr 366 (Rodrigues and Park, 1994) . These sites correspond to Tyr 1234 and Tyr 1235 which have the same role in the full size receptor . Both residues are essential for full activation of the enzyme, as they are responsible for the positive regulation of the HGF receptor enzymatic activity which is upregulated by an autocatalytic mechanism (Naldini et al., 1991a) . Tpr-Met downstream signaling has been elucidated. In the full size receptor, two sites (Tyr  1349 and Tyr   1356 ) located in the C-terminal tail are responsible for the association with SH2 domain-containing transducers Weidner et al., 1995) . The corresponding Tpr-Met tyrosines (Tyr  482 and Tyr   489 ) are involved in downstream signaling. In particular, Tyr 489 represents a multisubstrate binding site for Grb-2, Phospholipase-Cg (PLC-g), tyrosine phosphatase SHP-2, shc, Phosphatidyl Inositol-3 kinase (PI3K), Cbl and Gab-1 (for a review see Bardelli et al., 1997a) . Phosphorylation of this site is critical for ecient cellular transformation mediated by Tpr-Met Fixman et al., 1995 Fixman et al., , 1997 .
The TPR-MET rearrangement has also been detected in a number of human cell lines derived from human gastric carcinomas (Soman et al., 1990) and in biopsy samples derived from gastric tumors (Soman et al., 1991) . The Tpr-Met oncogenic potential has been evaluated both in ®broblasts in vitro and in transgenic mice, where it leads to the development of mammary tumors (Rodrigues and Park, 1993; Liang et al., 1996) .
During the TPR-MET rearrangement, the intracellular portion of the receptor is conserved, with the notable exception of the exon encoding the juxtamembrane domain. Interestingly, a naturally occurring splice variant of the Met receptor (Met juxta-), which lacks the exon encoding for the juxtamembrane domain, has been described in mouse tissues (Lee and Yamada, 1994) . The Met juxtavariant displays a dierent pattern of tyrosine phosphorylated proteins and associates stronger to p85 subunit of PI3K than the wild type form, suggesting an involvement of the juxtamembrane domain in the regulation of the interaction between Met and the signaling transducers (Lee and Yamada, 1995 (Gandino et al., 1990 (Gandino et al., , 1991 , down-modulating phosphorylation levels of the major phosphorylation sites (Gandino et al., 1994) . Tyr 1003 and its surrounding residues have also been implicated in receptor regulation by aecting Met-mediated biological responses (Weidner et al., 1995) .
Little is known about the negative regulation of Met signaling, but the above mentioned reports suggest that the juxtamembrane domain could represent a negative regulatory region. Therefore, its absence in the TPR-MET rearrangement could be a critical step in Met oncogenic conversion. In this work, we used a Tpr-Met variant which contains the juxtamembrane domain (Tpr-juxtaMet) to assess the eect of this region on the biochemical and biological properties elicited by the rearranged oncogene.
TPR-juxtaMET variant was generated by inserting the exon encoding the juxtamembrane domain between TPR and MET sequences (Figure 1) . Two additional TPR-juxtaMET mutants were also generated in which the serine corresponding to Ser 985 in the full size receptor was converted in Ala (TPR-juxtaMET , which modulate catalytic and biological activities are located in the juxtamembrane domain. In Tpr-juxtaMet these residues have also been replaced with alanine (S/A) and phenylalanine (Y/F) respectively. Y 1349 and Y
1356
, the signal transducers docking sites located in the tail, correspond to Y 482 and Y 489 in Tpr-Met and Tpr-juxtaMet. TprjuxtaMet residues are indicated maintaining the numbering of Tpr-Met. TPR-juxtaMET construct was obtained by insertion, at the site of the natural recombination between TPR and MET, of a PCR-ampli®ed fragment encoding the juxtamembrane domain of MET. The PCR ampli®cation was performed using oligonucleotides designed on the MET sequence (sense oligo: position 2916 ± 2946 and antisense oligo: position 3352 ± 3377) and using MET full size wild-type (Ponzetto et al., 1991) or mutated forms as a template. TPR sequence was obtained with a PCR ampli®cation using the forward primer, designed on 5' untranslated TPR sequence and the reverse primer designed to generate a restriction site at the fusion point between TPR and MET sequences, using TPR-MET as the template. The two PCR fragments were digested and cloned in frame into the pMT2 eukaryotic expression vector containing C-terminal MET sequence. The ®delity of the constructs was veri®ed by double strand DNA sequencing with T7 polymerase (Pharmacia, Uppsala, Sweden)
Vectors containing the TPR-MET or TPR-juxta-MET cDNAs were cotransfected with the psV2Neo vector in Fisher Rat (FR) ®broblasts. Cells were split and either used for focus forming assays or selected with G418 to obtain stable cell lines. As expected, TprMet was highly transforming while, surprisingly, the Tpr-juxtaMet variant was unable to transform Fisher Rat ®broblasts (Figure 2a ). Comparable results were obtained when the same experiment was performed using NIH3T3 cells (Figure 2b ). Transfected cells stably expressing Tpr-Met or Tpr-juxtaMet variants were obtained by G418 selection. Transfection eciency was comparable for all constructs. To assess the expression of recombinant proteins, cell lysates were immunoprecipitated with anti-Met antibody, separated by SDS ± PAGE and immunoblotted with anti-Met antibodies (Figure 3a) . The subcellular localization of Tpr-Met and Tpr-juxtaMet proteins was evaluated in transfected ®broblasts by immuno-¯u orescence staining. Figure 3b shows that both proteins display similar pattern of intracellular distribution. Altogether these experiments show that the juxtamembrane domain impairs the transforming ability of Tpr-Met without aecting its expression or its subcellular localization.
We next evaluated the transforming potential of the Tpr-juxtaMet variants carrying point mutations in the regulatory residues of the juxtamembrane domain (Tpr-juxtaMet Ser?Ala and Tpr-juxtaMet Tyr?Phe ). Figure  2b shows that mutations on these residues were not able to rescue the Tpr-Met oncogenic potential and thus neither this Serine or this Tyrosine were implicated in the inhibitory mechanism. The phosphorylation of Ser 985 is PKC-dependent (Gandino et al., 1990) . PKC is a membrane-anchored protein while Tpr-juxtaMet, like Tpr-Met, is located in the cytosol (Figure 3b ). The serine in Tpr-juxtaMet is therefore unlikely to be accessible to PKC as the two proteins are located in dierent subcellular compartments.
Pools of ®broblasts expressing comparable amounts of the two exogenous proteins (Tpr-Met and Tpr- Figure 2 Presence of the juxtamembrane domain abolishes TprMet transforming potential. Recombinant pMT2 vectors containing TPR-MET or TPR-juxtaMET cDNAs and empty vector were transfected in Fisher Rat ®broblasts. Cells were assayed for focus formation (a) as described in Santoro et al. (1996) . The same experiment, using TPR-MET, wild-type and mutated TPRjuxtaMET variants subcloned into the pCEV29.1 plasmid, was performed in NIH3T3 cells (b) as described in Michieli et al. (1996) . Numbers reported are means of triplicates (+s.d.). The inset shows a representative plate for each construct tested after 15 days from the transfection Figure 3 Exogenous stable expression and subcellular localization of Tpr-Met and Tpr-juxtaMet proteins. NIH3T3 pools of clones stably expressing Tpr-Met or Tpr-juxtaMet variants were obtained by G418 selection (0.7 mg/ml). To evaluate the level of exogenous expression (a), cells were lysed as described in Ponzetto et al. (1994) and extracts were immunoprecipitated with Mab anti-Met DQ13. Proteins were separated by SDS ± PAGE and transferred onto nitrocellulose. The ®lter was immunodecorated with C-12 anti-Met polyclonal antibody (Santa Cruz Biotechnology Inc.). Arrows indicate bands corresponding to Tpr-Met (60 KD) and Tpr-juxtaMet (70 KD). To analyse subcellular localization of Tpr-Met and Tpr-juxtaMet proteins (b), cells were ®xed with 3% paraformaldehyde, permeabilized with 1% Triton and decorated with C-12 anti-Met polyclonal antibody Santa Cruz Biotechnology Inc.). Stain was obtained after incubation with Texas Red linked to anti-Rabbit total Ig (Amersham Life Science) juxtaMet) were tested in a proliferation assay. Cells were plated at low density and then starved in low serum. Cell proliferation was evaluated at ®xed times by a colorimetric assay. Cells expressing Tpr-Met and Tpr-juxtaMet grew faster than parental cells, however, the doubling time of the cells expressing Tpr-juxtaMet was reduced by approximately 50% (Figure 4a ). The same cell lines were assayed for the ability to overgrow cell monolayers. Cell lines expressing Tpr-Met or TprjuxtaMet were diluted in medium containing an excess of parental ®broblast cells and then plated with low serum. After 1 week the ability of transfected cells to overgrow the parental monolayer was analysed by counting the number of foci. Cells expressing Tpr-Met were able to form large foci: on the contrary, TprjuxtaMet expressing cells showed a reduced number of small foci (Figure 4b ). The anchorage-independent growth of cells expressing Tpr-Met or Tpr-juxtaMet was evaluated using the soft agar assay. As expected, Tpr-Met expressing cells induced growth very efficiently. In contrast, Tpr-juxtaMet expressing cells were severely impaired as they resulted in a reduced number of colonies of smaller size (Figure 4c ).
The proliferative, motile and invasive potential of cells expressing Tpr-Met or Tpr-juxtaMet variants was evaluated using transwells. During this assay cells initially pass through ®lter pores and attach on the other side of the ®lter. This step can be used to monitor cell motility. Subsequently, cells can detach and dive into the lower compartment where they can form colonies. This step measures cell capacity to detach from a substrate, survive and proliferate. To measure cell invasiveness, both steps are monitored in the presence of an arti®cial basement membrane made mainly of laminin, collagen IV and heparan sulfate (Matrigel 1 : Albini et al., 1989) . Motility transwell assays showed that ®broblasts expressing Tpr-Met are highly motile. Although TprjuxtaMet cells display enhanced migration when compared to control cells, they are signi®cantly less motile compared to Tpr-Met cells (Figure 5a , upper panel). In addition, cells expressing Tpr-juxtaMet display a threefold reduction in the ability to invade (Figure 5b , upper panel). The inhibition exerted by the juxtamembrane domain is particularly evident when the cell-dividing ability is measured (both in the presence and in the absence of Matrigel). In this case, Tpr-Met cells showed an ability to detach, survive and proliferate tenfold higher than Tpr-juxtaMet cells (Figure 5a and b, lower panels).
Altogether, these experiments demonstrate that the presence of the juxtamembrane domain strongly inhibits the biological responses mediated by TprMet including proliferation, motility, invasion and transformation. A number of explanations may account for this inhibitory eect exerted by the juxtamembrane domain. One possibility is that TprMet biological activities could be down-modulated as a result of a reduced kinase activity. To evaluate this hypothesis, we compared the in vitro kinase activities of Tpr-Met and Tpr-juxtaMet by evaluating the kinetics of autophosphorylation. Proteins were immunopuri®ed from cell lysates and subjected to an in vitro kinase assay in the presence of [g-32 P]ATP ( Figure  6a and b) . The enzymatic behavior of the two proteins was comparable. The same results were obtained measuring the kinetics of phosphorylation of an exogenous substrate (data not shown). These experiments indicate that the presence of the juxtamembrane domain does not in¯uence Tpr-Met kinase activity. To assess the phosphorylation state of Tpr-Met and TprjuxtaMet proteins in intact cells, lysates from stable transfectant ®broblasts were immunoprecipitated with anti-Met antibody, separated by SDS ± PAGE and immunoblotted with anti-pTyr antibodies. No differences in the overall levels of phosphorylation were observed (Figure 6c ). It should be noted that this kind of assay measures phosphorylation of the major phosphorylation sites, corresponding to Tyr 365 and Tyr 366 (Rodrigues and Park, 1994; Naldini et al., 1991a) , thus we conclude that Tpr-Met and TprjuxtaMet Tyr 365,366 are phosphorylated at the same level. Altogether these experiments indicate that the ) and anchorageindependent growth (c) assays. In (a) proliferation in low serum condition was estimated at ®xed times as indicated by a colorimetric method. Reported numbers are means of quintuplicates (+s.d.). Overgrowth was evaluated co-colturing for 1 week in low serum a mixed population of parental and transfected cells (respectively 100 : 1 ratio) as described in Fixman et al. (1995) . Representative plates are shown in b. Anchorage-independent growth was assessed by soft-agar assay (performed as described in Giordano et al., 1997) . In c the number of colonies grown after 15 days is reported as mean of triplicates (+s.d.) presence of the juxtamembrane domain does not aect the Met catalytic activity resulting in the same overall tyrosine phosphorylation level.
Tpr-Met signaling depends on phosphorylation of two tyrosine residues (Tyr 482 and Tyr
489
) located in the receptor tail which act as multifunctional binding sites for a number of signal transducers. Phosphorylation of these sites is critical for Tpr-Met-mediated transformation and invasion Fixman et al., 1995 Fixman et al., , 1997 . Among proteins involved in Met downstream signaling, the two adaptor molecules Grb-2 and Gab-1 play a central role. Binding of Grb-2 to Tyr 489 initiates the sos-ras pathway and is required for TprMet mediated transformation (Ponzetto et al., 1996) ; the interaction of Gab-1 with Tyr 482 and Tyr 489 promotes the recruitment of transducers such as PI3Kinase that, in turn, control motility and invasion (Giordano et al., 1997; Bardelli et al., 1999) . To assess the role of the juxtamembrane domain on the regulation of Tpr-Met signaling, we compared the interaction of Tpr-Met and Tpr-juxtaMet with either Grb-2 and Gab-1 using pull-down experiments. As discussed above, by assessing the direct binding with these adaptors we also measure the ability of Tpr-Met and Tpr-juxtaMet to associate and activate the other signal transducers. Fibroblasts expressing Tpr-Met or Tpr-juxtaMet were lysed in the presence of phosphatase inhibitors, then the lysates were incubated with puri®ed GST-Grb2 or with puri®ed GST-Met Binding Domain (MBD) of Gab-1 immobilized on glutathione sepharose. The amount of Tpr-Met or Tpr-juxtaMet proteins associated to the GST-fusion proteins was revealed by immunoblotting with anti-Met antibodies. As shown in Figure 7 , Tpr-Met binds both Grb-2 (a) and MBD-Gab1 (b) more eciently than TprjuxtaMet. These data indicate that the tail of TprjuxtaMet has a reduced ability to bind downstream adaptors and transducers, suggesting that unlike the major phosphorylation site (1996) . Cells, seeded on the upper compartment, ®rst passed to the other side of the ®lter, then detached and after diving, attached to the bottom of lower compartment. To measure motility, cells were allowed to migrate for 6 h on the lower side. Cell number was then evaluated using a colorimetric assay (a, upper panel) . After 24 h the number of cells in the lower well was also evaluated (a, lower panel). To measure cell invasion, ®lters were coated with a reconstituted basal membrane (Matrigel). Cells that, after 24 h incubation, had crossed the Matrigel and attached to lower side of the ®lter were scored as above (b, upper panel) . After 48 h cells dived in the lower well were also counted (b, lower panel). Optical density and cell numbers reported are means of duplicates (+s.d.) lysed in the presence of phosphatase inhibitors and an equal amount of total proteins were separated by SDS ± PAGE. Comparable level of MAP kinase protein was assessed by immunoblotting with anti-MAP kinase antibodies (data not shown). MAP kinase activation was evaluated by immunoblotting with an antibody that selectively reacts with MAP kinase phosphorylated forms. As expected, in Tpr-Met cells the phosphorylation of MAP kinase was higher than in the control cells. Conversely, in cells expressing Tpr-juxtaMet phosphorylation of the MAP kinase was reduced to basal level. These results indicate that the juxtamembrane domain impairs the Tpr-Met signaling pathway leading to MAP kinase activation (Figure 7c ). This in turn may lead to the Tpr-juxtaMet reduced biologic responses. The signaling impairment conferred by the juxtamembrane domain could be due to an associated inhibitory activity(s) which modulates the level of phosphorylation of the signal transducer docking sites (Tyr  482 and Tyr   489 ). Previous data provided evidence that a tyrosine phosphatase activity associates with the activated Met receptor (Villa-Moruzzi et al., 1993) . More recently, we described the interaction of Met with PTP-S (Villa-Moruzzi et al., 1998) a soluble phosphatase located in the cytoplasm and in the nucleus of a variety of cells (Radha et al., 1994) . PTP-S interacts with the juxtamembrane domain of the Met and has been implicated in regulation of cell proliferation (Kamatkar et al., 1996) . It is possible that by binding PTP-S the juxtamembrane region exerts its inhibitory role on Met signaling which, in turn, negatively aects Met-mediated biological responses. A kinase assay was performed on the immunoprecipitates for the indicated ®xed times as previously described (Naldini et al., 1991a) . (a) Shows the autoradiography analysis. Quanti®cation of bands by optical density is shown in (b). Proteins from the same immunoprecipitates were directly subjected to SDS ± PAGE and transferred onto nitrocellulose. The ®lter was immunodecorated with anti-phosphotyrosine monoclonal antibodies (Upstate Biotechnology Incorporated, USA) to compare overall tyrosine phosphorylation levels (c). Arrows indicate bands corresponding to Tpr-Met (60 KD) and Tpr-juxtaMet (70 KD) Figure 7 Tpr-juxtaMet interacts with signal transducers and induces Map Kinase activation less eciently than Tpr-Met.
Lysates from ®broblasts expressing Tpr-Met or Tpr-juxtaMet, prepared as described in Ponzetto et al. (1994) were incubated in the presence of phosphatase inhibitors either with GST-Grb2 (a) or with Gab-1 GST-MBD domain (b) immobilized on glutathione sepharose Bardelli et al., 1997b) . The amount of Tpr-Met or Tpr-juxtaMet proteins associated with Grb-2 or with the MBD domain was revealed by immunoblotting with anti-Met antibodies (C-12). Arrows indicate bands corresponding to Tpr-Met (60 KD) and Tpr-juxtaMet (70 KD). Quanti®cation of the bands by optical density indicates a fourfold and a 2.5-fold inhibition in the association respectively to Grb-2 and Gab-1 MBD domain. c shows phosphorylation level of MAP kinase. Total cell lysates from ®broblasts expressing TprMet, TprjuxtaMet or transfected with the empty vector prepared as described in Ponzetto et al. (1994) were analysed by SDS ± PAGE and Western immunoblotting with anti-active MAP kinase antibody (Promega Corporation, USA). Arrows indicate the bands corresponding to MAP kinase active forms p42 ERK1 and p44
ERK2
It is tempting to speculate that in Tpr-juxtaMet, the positive action of the TPR dimerization motif is counterbalanced by the eect of the phosphatase, which dephosphorylates the tyrosines involved in binding signaling molecules. This would result in a constitutively activated kinase which is devoid of signaling potential and therefore unable to elicit the full biological response.
In conclusion, we propose that during the rearrangement, the loss of the exon encoding for the juxtamembrane domain is crucial in the generation of the transforming potential of TPR-MET. This splicing event is in fact essential to remove a domain with an intrinsic negative role on Met downstream signaling.
